Market capitalization | $45.19m |
Enterprise Value | $39.51m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.68 |
P/S ratio (TTM) P/S ratio | 0.78 |
P/B ratio (TTM) P/B ratio | 1.88 |
Revenue growth (TTM) Revenue growth | -31.76% |
Revenue (TTM) Revenue | $57.68m |
As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.
2 Analysts have issued a Fortress Biotech, Inc. forecast:
2 Analysts have issued a Fortress Biotech, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 58 58 |
32%
32%
|
|
Gross Profit | 32 32 |
42%
42%
|
|
EBITDA | -104 -104 |
21%
21%
|
EBIT (Operating Income) EBIT | -111 -111 |
20%
20%
|
Net Profit | -46 -46 |
24%
24%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Fortress Biotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel pharmaceutical and biotechnology products. It operates through the following segments: Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The company was founded on June 28, 2006 and is headquartered in New York, NY.
Head office | United States |
CEO | Lindsay Rosenwald |
Employees | 101 |
Founded | 2006 |
Website | www.fortressbiotech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.